Maintenance Therapy in AML: What Is the Future Potential?
Journal Title
American Journal of Hematology
Publication Type
Review
Abstract
Over the last decade, there have been significant advancements in the treatment for patients with acute myeloid leukemia (AML) including the addition of novel, targeted agents to intensive or nonintensive chemotherapy regimens. However, despite this, the majority of patients will still ultimately relapse and long-term survival remains poor. While the use of maintenance therapy has emerged as a potential strategy to maintain more durable remissions and improve overall survival, the optimal use of these therapies has not yet been clearly defined. In this review, we provide a comprehensive overview of the evolution of maintenance strategies in AML and present a commentary on the future of maintenance therapy, including the pressing, unmet needs in this field.
Publisher
Wiley
Keywords
Humans; *Leukemia, Myeloid, Acute/drug therapy/mortality; *Maintenance Chemotherapy; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Remission Induction; Aml; AML molecular diagnosis and therapy; chemotherapy; leukemia
Department(s)
Haematology
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2025-03-18 06:23:44
Last Modified: 2025-03-18 06:24:11

© 2025 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙